AbbVie, Medincell to Develop Next-gen Long-acting Injectable Therapies

 Medincell will receive an upfront payment of $35 million and is eligible for up to $1.9 billion in potential development and commercial milestones, plus royalties on worldwide sales.

Medincell and AbbVie will co-develop, and AbbVie will commercialize up to six cutting-edge long-acting injectables (LAI).

The first LAI program candidate has been selected and formulation activities are underway.

This pivotal alliance leverages Medincell's commercial-stage LAI technology and development know-how, and AbbVie's extensive clinical development and commercialization expertise, to deliver innovative therapeutic solutions to patients globally.

https://www.businesswire.com/news/home/20240415101781/en/Medincell-Enters-Into-Strategic-Co-development-and-Licensing-Agreement-with-AbbVie-to-Develop-Next-generation-Long-acting-Injectable-Therapies